Geron (GERN) Gets ODAC Votes for Blood Disorder Drug, Shares Up

Geron Corporation (GERN) announced that the FDA Oncologic Drugs Advisory Committee (ODAC) voted in favor of the clinical benefit/risk profile of pipeline candidate, imetelstat, for the treatment of transfusion-dependent (TD) anemia in adult patients with low-to-intermediate-1 risk myelodysplastic syndromes (LR-MDS) who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs).The ODAC voted 12:2 in favor of imetelstat’s benefits over risks.Consequently, sh ...